Linfoma primario de bazo. Presentación de un caso / Primary lymphoma of the spleen. Case presentation

Fundamento: en el bazo se pueden observar diferentes tipos de tumores, dentro de los cuales están los linfomas primarios del mismo, enfermedad infrecuente, de ahí la importancia de su presentación. Presentación de caso: paciente femenina de 66 años, raza blanca, con antecedentes de hipertensión arterial, lobectomía derecha del tiroides, que refiere venía presentando desde hacía más de un año dolor abdominal alto izquierdo que se hacía más intenso tras el esfuerzo físico, tos, presentando toma del estado general por lo que se ingresa en el servicio de cirugía. Se toman muestras para biopsia, después de ser intervenido quirúrgicamente de una esplenectomía, dando como resultado un Linfoma no Hodgkin de células grandes CD20 positivo, sin infiltración hepática, ganglionar ni epiplóica. Se realizó esplenectomía y quimioterapia. La paciente ha evolucionado favorablemente. Conclusiones: el linfoma primario de bazo es una entidad infrecuente y su diagnóstico es aún más raro en pacientes por encima de los 60 años, como ocurrió en el caso presentado. A medida que casos como este se divulguen entre los profesionales de la salud permitirán una aproximación diagnóstica más precisa a esta enfermedad poco común.

Background: in the spleen you can see different types of tumors; primary lymphomas are an example of them. This is an infrequent disease, hence the importance of its presentation. Case presentation: 66 year old white female patient with history of hypertension, thyroid right lobectomy that refers to have been suffering from high left abdominal pain for a year that became more intense after physical exertion, cough, presenting general malaise by what is admitted to the surgical service. Some samples for biopsy are taken, after being surgically operated of a splenectomy, showing as a result a non-Hodkin lymphoma of big cells resulting cell non-Hodgkin lymphoma CD20 Positive, without hepatic, ganglionic or epiploic infiltration. Splenectomy and chemotherapy were made. The patient has improved favorably. Conclusions: primary lymphoma of the spleen is a rare entity and its diagnosis is still rarer in patients over 60 years, as it happened in the case presented. As cases like these are disseminated among health professionals will allow a more accurate diagnostic approach to this rare disease.

Immunohistochemical analysis for CD21, CD35, Caldesmon and S100 protein on dendritic cells types in oral lymphomas

OBJECTIVE: Follicular dendritic cells (FDCs) and interdigitating dendritic cells (IDCs) are dendritic cells found in lymphoid follicles, reactive follicles and in lymphomas. The goal of this study was to evaluate the presence and distribution of FDCs and IDCs in oral lymphomas. MATERIAL AND METHODS: Immunohistochemistry reactions were applied to 50 oral lymphomas using the antibodies anti-CD21, anti-CD35 and anti-caldesmon to FDCs, and anti-S100 protein to IDCs. Caldesmon+/FDCs and S100+/IDCs were quantified in Imagelab® software. RESULTS: FDCs revealed by CD21 and CD35 were positively stained in two cases of diffuse large B-cell lymphoma, one MALT lymphoma, and in one case of mantle cell lymphoma. FDCs were immunopositive to caldesmon in all cases, as well as IDCs to S100 protein. Burkitt lymphoma presented a lower amount of caldesmon+/FDCs and S100+/IDCs than diffuse large B-cell lymphoma and plasmablastic lymphoma of the oral mucosa type. CONCLUSIONS: The microenvironment determined by neoplastic lymphoid cells in oral lymphomas is responsible by the development and expression of dendritic cells types.

Valor pronóstico de los niveles séricos del CA-125 en pacientes con linfoma no hodgkin / Prognostic value of serum CA 125 levels in non-hodgkin's lymphoma patients

El CA 125 ha sido considerado un nuevo marcador pronóstico en linfoma No Hodgkin (LNH). El objetivo del trabajo consistió en evaluar la significancia pronostica de los niveles del CA 125 en pacientes con LNH, asociación y correlación con factores clínicos patológicos, biológicos y sobrevida. Se procesaron muestras de suero de 67 pacientes con diagnóstico de LNH, de primera consulta, pretratamiento, VIH negativo y sin presentar otras enfermedades, edad promedio 55 años (rango 18-79 años), LNH agresivos 49 (73%) y LNH indolentes 18 (27%), IPI 60 (90%) de bajo riesgo y 7 (10%) de alto riesgo, tiempo promedio de seguimiento 30 meses (rango 3-48 meses). CA 125, B2M e IL-6 se determinaron por inmunoensayos enzimáticos y Proteína C Reactiva, Albúmina sérica, LDH, AST, ALT y fosfatasa alcalina por métodos de aglutinación directa, colorimétrico y cinético, respectivamente. 16 (24%) de los pacientes expresaron niveles elevados de CA 125 (>35u/ml) (p<0,001). Asociación significativa (p≤0,05) de CA 125 (35u/ml) con estadío clínico (EC) III-IV, enfermedad voluminosa (EV)>10cm, síntomas B (SB), enfermedad abdominal (EAb) y níveles elevados de LDH y B2M. Correlación significativa y directa con EC, EV, SB, LDH, B2M y AST (p≤0,05) y correlación inversa con albúmina sérica (p=0,02). El análisis univariado mostró una significativa disminución de la sobrevida global en los pacientes con LNH agresivos y niveles elevados de CA 125(>35u/ml) (p=0,03), LDH (p=0,048) y B2M(p=0,02). Según el análisis multivariado, Ca 125 perdió su significancia, LDH (p=0,04) y B2M (p=0,003) mantuvieron su valor pronóstico independiente. Los resultados del presente trabajo sugieren la utilidad pronóstica de los niveles séricos del CA 125, siendo recomendable su inclusión en la evaluación clínica inicial e los pacienten con LNH.

CA 125 has been considered a new prognostic marker in Non-Hodgkin lymphoma (NHL). The objetive of this study was to determine the prognostic significance of CA 125 levels in NHL patients, the association and correlation with clinical pathological and biological factos and survival. We processed 67 serum samples from newly diagnosed NHL patients previously untreated, HIV-negative and free from other diseases, mean age 55 years (range 18-79 Years), agressive NHL 49 (73%) and indolent NHL 18 (27%), IPI: 60 (90%) of low risk and 7 (10%) high risk, the average time of follow up was 30 months (range 3-48 months). CA 125, B2M and IL-6 were determined by enzyme immunoassay methods. C-reactive protein, serum albumin, LDH, AST, ALT and alkaline phosphatase were determined by direct agglutination, colorimetric and kinetic methods, respectively. Elevted levels of CA 125 (>35u/ml) were expressed in 16 (24%) of the patients (p<0.001). CA 125 levels (>35u/ml) were significantly (p≥0.05) associated with the follwing factors: clinicals stage (CS) III-IV, bulky disease (BD)>10 cm, B symptoms (BS), abdominal disease (ABD) and elevated levels of LDH and B2M. There was a significant and direct correlation (p≤0.05) with CS, BD, BS, LDH, B2M and AST and inversely with serum albumin (p=0,02). Univariate analysis showed a significant decreased of overall survival in patients with aggressive NHL with elevated levels of CA 125 (p<0.048), LDH (p=0.048) and B2M (p=0,02). In multivariate analysis Ca 125 lost its prognostic significance, LDH (p=0.04) and B2M (p=0.003) remained their independent prognostic value. The results of this study suggest the prognostic value of serum levels of CA 125, being recommended for inclusion in the initial clinical evaluation of patients with NHI.

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6 percent) or persistent or relapsed Hodgkin's disease (39.4 percent) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15 percent, respectively (P<0.0001). Overall survival was 92 percent for chemosensitive patients and 0 percent for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12 percent (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment

T cell rich B cell lymphoma (TCRBCL): study of sixteen cases with review of literature.

T cell rich B cell lymphoma (TCRBCL) is a recently described variant of diffuse non Hodgkin's lymphoma (NHL), the acronym of which has gained wide acceptance among hematopathologists in a relatively shorter period of time. The recognition of this entity requires immunohistochemical facilities especially on paraffin embedded tissues. TCRBCL is one of the many examples in the diagnostic anatomic pathology which emphasizes the need of immunocytochemistry and availability of this technique at least in referral laboratories. One of the differential diagnosis in this case includes lymphocyte predominance Hodgkin's disease (LPHD) which is the most favorable prognostic histologic subtype of Hodgkin's disease (HD) while TCRBCL is an aggressive B Cell NHL and should be treated as high grade large cell lymphoma. The other close differential includes peripheral T cell non-Hodgkin's lymphoma (PTCL). We reported sixteen (16) cases of TcRBCL diagnosed during a period of two and a half years (January 1995 to June 1997). HD and PTCL were the main differential diagnoses in most of these cases. The median age at diagnosis was 39 years and male to female ratio was equal. TCRBCL was nodal in location in 15 cases and a single case in extranodal site presenting as spinal tumor. The mean neoplastic B cell population was 12%, while that of reactive T cells was 82%. A significant polymorphous inflammatory cellular background was noted in 5 cases. Reed-Stenberg like cells were observed in 3 cases. Immunoglobulin light chain restriction studies were performed in fourteen cases and revealed lambda light chains in ten cases while in four cases kappa light chains were present.

Esquemas de quimioterapia de linfomas / Scheme of chemoterapy lynphoma

Se presenta este tema en el 1er. Simposium Internacional de Linfomas, considerando de interés que es de gran ayuda tener a la mano un formato de bolsillo con la actualización de los esquemas de la quimioterapia tanto para la enfermedad de Hodkin como para los linfomas no-hodgkin